News
The NNF – a philanthropic non-profit organisation that owns a controlling stake in Danish drugmaker Novo Nordisk – has been ...
The Obesity Drug Development Summit Europe is your perfect platform to be in a prime position to be at the forefront of this ...
The Synthetic Human Genome (SynHG) Project, launched on the 25th anniversary of the mapping of the human genome, is being ...
The Neuropsychiatric Drug Development Summit returns for its eighth year as the industry’s flagship forum capturing ...
The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...
At Longeveron, Dr. Joshua Hare and his team are working on an Alzheimer’s treatment using human-derived bone marrow ...
The UK is studying cases of pancreatitis in people taking drugs based on GLP-1 receptor agonists for weight loss or type 2 ...
An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first ...
The licensing deal for BAFF/APRIL inhibitor telitacicept, which also includes regulatory and commercial milestones exceeding ...
Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...
It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...
Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results